OBJECTIVES: We have previously reported reduced serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) in schizophrenic patients. A single-nucleotide polymorphism (SNP) of the ICAM-1 gene was described at position 241. The G-->A SNP results in a nonsynonymous amino acid exchange of the ICAM-1 protein, and the A allele was shown to be also associated with several immunological disorders like rheumatoid arthritis. METHODS: We investigated 70 schizophrenic patients and 128 unrelated healthy control persons regarding the relationship between the serum levels of sICAM-1 and the ICAM-1 G214A polymorphism. RESULTS: We were able to replicate our previous finding of reduced sICAM-1 levels in schizophrenia. Healthy control persons carrying the polymorphic A allele showed markedly lower sICAM-1 serum levels than carriers of the homozygous GG wild type (p < 0.004). In contrast, no significant difference in the sICAM-1 serum levels were seen regarding the G241A genotype distribution in schizophrenic patients. CONCLUSION: We hypothesize that the biochemical effect of the G241A SNP is masked in schizophrenic patients, indicating a disease-related mechanism leading to reduced levels of sICAM-1 in schizophrenia.
OBJECTIVES: We have previously reported reduced serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) in schizophrenicpatients. A single-nucleotide polymorphism (SNP) of the ICAM-1 gene was described at position 241. The G-->A SNP results in a nonsynonymous amino acid exchange of the ICAM-1 protein, and the A allele was shown to be also associated with several immunological disorders like rheumatoid arthritis. METHODS: We investigated 70 schizophrenicpatients and 128 unrelated healthy control persons regarding the relationship between the serum levels of sICAM-1 and the ICAM-1G214A polymorphism. RESULTS: We were able to replicate our previous finding of reduced sICAM-1 levels in schizophrenia. Healthy control persons carrying the polymorphic A allele showed markedly lower sICAM-1 serum levels than carriers of the homozygous GG wild type (p < 0.004). In contrast, no significant difference in the sICAM-1 serum levels were seen regarding the G241A genotype distribution in schizophrenicpatients. CONCLUSION: We hypothesize that the biochemical effect of the G241A SNP is masked in schizophrenicpatients, indicating a disease-related mechanism leading to reduced levels of sICAM-1 in schizophrenia.
Authors: Emelia J Benjamin; Josée Dupuis; Martin G Larson; Kathryn L Lunetta; Sarah L Booth; Diddahally R Govindaraju; Sekar Kathiresan; John F Keaney; Michelle J Keyes; Jing-Ping Lin; James B Meigs; Sander J Robins; Jian Rong; Renate Schnabel; Joseph A Vita; Thomas J Wang; Peter W F Wilson; Philip A Wolf; Ramachandran S Vasan Journal: BMC Med Genet Date: 2007-09-19 Impact factor: 2.103
Authors: Kirsten Wedervang-Resell; Thor Ueland; Pål Aukrust; Svein Friis; Kirsten B Holven; Cecilie H Johannessen; Tove Lekva; Vera Lonning; Runar E Smelror; Attila Szabo; Ole A Andreassen; Anne M Myhre; Ingrid Agartz Journal: NPJ Schizophr Date: 2020-08-18
Authors: Sophie Meixensberger; Hanna Kuzior; Bernd L Fiebich; Patrick Süß; Kimon Runge; Benjamin Berger; Kathrin Nickel; Dominik Denzel; Miriam A Schiele; Maike Michel; Simon Maier; Karl Bechter; Katharina Domschke; Ludger Tebartz van Elst; Dominique Endres Journal: Diagnostics (Basel) Date: 2021-06-22